HALLE, Germany I November 12, 2013 I Scil Proteins Production, a private contract manufacturer of recombinant proteins, today announced that Wacker Biotech GmbH, a subsidiary of Wacker Chemie AG, has acquired 100% of its shares from the sole holder in the Company, BioNet Ventures GmbH. The transaction is expected to close at the beginning of 2014. Both companies are committed to a seamless transfer of business assets, as well as a smooth transition for the employees to WACKER.
Under the terms of the agreement, WACKER will acquire all assets of Scil Proteins Production, including its manufacturing site and patent portfolio. The business of the sister company Scil Proteins GmbH, including the Affilin® discovery platform and its corresponding service portfolio of lead identification and lead optimization services, remains unaffected and in sole ownership of BioNet Ventures GmbH.
Commenting on the sale of Scil Proteins Production, Dr. Ulrike Fiedler, CEO of Scil Proteins Production, said: “Since incorporation in 2005, the business has evolved into a successful microbial process developer and manufacturer with a proven track record, including worldwide manufacturing of the products Rapilysin® and Retavase®. With this transaction, the new company combines world-class know-how in E.coli refolding and secretion technologies and complementary manufacturing scales, which will bring value to our collective client base. We are proud of our achievements to date and are confident that we have found the right partner to take the business forward and succeed in the future.”
Dr. Gerhard Schmid, President of the WACKER BIOSOLUTIONS business division, said: “Integrating Scil Proteins Production into WACKER is an important step to further enable us to support our clients following drug approval. We will have access to know-how, highly qualified and experienced experts and a state-of-the-art, EMA-approved GMP manufacturing facility with a high production capacity. This is a milestone in the growth strategy of our biotechnology services and we look forward to a combined future. SCIL’s refolding expertise complements our own technology platforms and extends the range of services that we offer as a leading contract manufacturer of biopharmaceutical proteins with microbial technologies.”
About Scil Proteins Production
Scil Proteins Production has a longstanding expertise in protein production and development and offers GMP contract biomanufacturing and process development to biotech and pharma companies. With state of the art equipment and a particular expertise at refolding proteins, Scil Proteins Production has an excellent track record in supplying a top level support for its partners. Scil Proteins Production has supported a number of different companies in process development and biomanufacturing. Scil Proteins is a well-established private company located in Halle, Germany.
About Wacker Biotech
Wacker Biotech GmbH is a full-service contract manufacturer of bio-pharmaceutical products based on microbial systems. Services at the company’s certified multi-purpose site in Jena range from the field of molecular biology to comprehensive analytical services and process development, through the GMP-compliant production of clinical test samples as well as pharmaceuticals for the commercial market. Above all, Wacker Biotech offers proprietary technologies that satisfy market needs for cost-efficient production and maximum quality. Jena-based Wacker Biotech is a wholly-owned WACKER subsidiary.
SOURCE: Scil Proteins
Post Views: 195
HALLE, Germany I November 12, 2013 I Scil Proteins Production, a private contract manufacturer of recombinant proteins, today announced that Wacker Biotech GmbH, a subsidiary of Wacker Chemie AG, has acquired 100% of its shares from the sole holder in the Company, BioNet Ventures GmbH. The transaction is expected to close at the beginning of 2014. Both companies are committed to a seamless transfer of business assets, as well as a smooth transition for the employees to WACKER.
Under the terms of the agreement, WACKER will acquire all assets of Scil Proteins Production, including its manufacturing site and patent portfolio. The business of the sister company Scil Proteins GmbH, including the Affilin® discovery platform and its corresponding service portfolio of lead identification and lead optimization services, remains unaffected and in sole ownership of BioNet Ventures GmbH.
Commenting on the sale of Scil Proteins Production, Dr. Ulrike Fiedler, CEO of Scil Proteins Production, said: “Since incorporation in 2005, the business has evolved into a successful microbial process developer and manufacturer with a proven track record, including worldwide manufacturing of the products Rapilysin® and Retavase®. With this transaction, the new company combines world-class know-how in E.coli refolding and secretion technologies and complementary manufacturing scales, which will bring value to our collective client base. We are proud of our achievements to date and are confident that we have found the right partner to take the business forward and succeed in the future.”
Dr. Gerhard Schmid, President of the WACKER BIOSOLUTIONS business division, said: “Integrating Scil Proteins Production into WACKER is an important step to further enable us to support our clients following drug approval. We will have access to know-how, highly qualified and experienced experts and a state-of-the-art, EMA-approved GMP manufacturing facility with a high production capacity. This is a milestone in the growth strategy of our biotechnology services and we look forward to a combined future. SCIL’s refolding expertise complements our own technology platforms and extends the range of services that we offer as a leading contract manufacturer of biopharmaceutical proteins with microbial technologies.”
About Scil Proteins Production
Scil Proteins Production has a longstanding expertise in protein production and development and offers GMP contract biomanufacturing and process development to biotech and pharma companies. With state of the art equipment and a particular expertise at refolding proteins, Scil Proteins Production has an excellent track record in supplying a top level support for its partners. Scil Proteins Production has supported a number of different companies in process development and biomanufacturing. Scil Proteins is a well-established private company located in Halle, Germany.
About Wacker Biotech
Wacker Biotech GmbH is a full-service contract manufacturer of bio-pharmaceutical products based on microbial systems. Services at the company’s certified multi-purpose site in Jena range from the field of molecular biology to comprehensive analytical services and process development, through the GMP-compliant production of clinical test samples as well as pharmaceuticals for the commercial market. Above all, Wacker Biotech offers proprietary technologies that satisfy market needs for cost-efficient production and maximum quality. Jena-based Wacker Biotech is a wholly-owned WACKER subsidiary.
SOURCE: Scil Proteins
Post Views: 195
